ALNY Dennis A Ausiello sells $13.9M worth of shares
Aug 16, 2025, 4:34 AM
0.00%
What does ALNY do
Alnylam Pharmaceuticals, based in Cambridge, Massachusetts, specializes in mRNA cell therapies for autoimmune diseases, with its lead candidate Descartes-08 in Phase IIb trials for generalized myasthenia gravis. The company also develops Descartes-15 and Descartes-33, targeting B cell maturation antigen and autoimmune drivers, respectively.
Dennis A Ausiello sold 31,448 shares of ALNY on 14 August at $442.66 per share, worth a total of $13.9M. They now own 30,374 ALNY shares, or a 97% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
